Yasmine Elamir, MD
Internal Medicine · Jersey City, NJNPI 1467807438
Payments from drug & device makers
Across 397 payments — averaging $118.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$37K
- Xeris Pharmaceuticals, Inc.$5K
- Medtronic$710
- Corcept Therapeutics$682
- Novo Nordisk$526
- Dexcom, Inc.$423
- plus $3K from 35 others
What the payments were for
- Speaking & faculty fees$40,27385%
- Travel & lodging$5351%
- Food & beverage$6,26113%
- Education$200%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 80 | $36,852 |
| Xeris Pharmaceuticals, Inc. | 13 | $4,837 |
| Medtronic | 28 | $710 |
| Corcept Therapeutics | 46 | $682 |
| Novo Nordisk | 32 | $526 |
| Dexcom, Inc. | 14 | $423 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $371 |
| Mannkind Corporation | 24 | $357 |
| Insulet Corporation | 14 | $269 |
| Amgen(2 entities) | 16 | $248 |
| AstraZeneca | 13 | $226 |
| Sanofi-aventis U.S. LLC | 12 | $199 |
| Amneal Pharmaceuticals LLC | 9 | $155 |
| Bayer | 8 | $154 |
| GSK | 10 | $141 |
| Cequr Corporation | 2 | $121 |
| Boehringer Ingelheim | 7 | $99 |
| Intra-sana Laboratories | 6 | $93 |
| Tandem Diabetes Care, Inc. | 3 | $89 |
| Abbott | 4 | $74 |
| Astellas Pharma US Inc | 3 | $53 |
| 3b Medical, Inc. | 1 | $45 |
| AbbVie | 3 | $40 |
| Madrigal Pharmaceuticals | 2 | $39 |
| Electromed, Inc. | 2 | $34 |
| Novartis | 2 | $31 |
| Althera Pharmaceuticals LLC | 2 | $29 |
| Biogen | 1 | $28 |
| Nevro Corp. | 1 | $25 |
| BETA Bionics, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$35,935
- RECORLEV$4,695
- DEXCOM G7 GSS (161)$125
How this compares
$47,148 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 586 | $682,686 |
| OzempicSemaglutide | 562 | $597,676 |
| JardianceEmpagliflozin | 310 | $332,811 |
| FarxigaDapagliflozin Propanediol | 233 | $238,809 |
| JanuviaSitagliptin Phosphate | 122 | $122,430 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $91,824 |
| TrulicityDulaglutide | 78 | $90,427 |
| TezspireTezepelumab-Ekko | 11 | $45,736 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $44,433 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $42,001 |
| TradjentaLinagliptin | 52 | $39,086 |
| LinzessLinaclotide | 39 | $37,799 |
| RybelsusSemaglutide | 22 | $30,780 |
| ProliaDenosumab | 18 | $30,318 |
| EliquisApixaban | 39 | $30,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $36,852 | $779,750679 claims |
| Novo NordiskOzempic, Rybelsus | $526 | $628,456584 claims |
| Boehringer IngelheimJardiance, Tradjenta | $99 | $371,898362 claims |
| AstraZenecaFarxiga, Tezspire, Breztri Aerosphere, Symbicort | $226 | $299,980282 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $141 | $107,908172 claims |
| GileadGenvoya | $14 | $42,00111 claims |
| AbbVieLinzess | $40 | $37,79939 claims |
| AmgenProlia | $248 | $30,31818 claims |
| PfizerEliquis | $18 | $30,26639 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $371 | $17,85914 claims |
| Astellas Pharma US IncVeozah | $53 | $7,25911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Jersey City
- Nana SafoaahJersey City$229K
- Amer SyedJersey City$140K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.